Article | December 11, 2023

A Lean, Agile Business Model To Deliver High-Quality Oncologic Treatments

Source: Cytiva

Prior to his foray into the C-suite of a lean biotech, Nadim Ahmed spent his career in clinical development, medical affairs, and business management. Now, having taken the helm as President and CEO at Cullinan Oncology, his team is leveraging speed and innovation to bring new oncologic treatments to patients. As a small, clinical-stage company, Cullinan must prioritize resources and be nimble as they identify only the most effective candidates to bring to the clinic. Though easier said than done, by using their modality-agnostic discovery process, the Cullinan team has built a diverse, efficient approach that is empowering them on their path to becoming a fully integrated commercial biotech company.

In an episode of The Business of Biotech podcast, Ahmed explained that while he didn’t set out to become a leader in biotech, he recognized opportunities at Cullinan that he couldn’t pass up. Download the full article to learn more about how Cullinan is designing an exciting model that emphasizes the importance of culture, strategy, and execution.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development